腾盛博药-B（股票代码：02137）于2026年9月4日公布截至2026年8月31日的股份变动月报表。公告显示，公司法定/注册股本合计维持在1,200,000,000股普通股，面值为每股USD 0.000005，总额USD 6,000，与上月末保持一致。
月报显示，截至7月底，公司已发行股份（不含库存股份）为721,978,947股，期末增加55,793股至722,034,740股；库存股份由12,723,500股增至12,923,500股，总股本由734,702,447股增至734,958,240股。上述股份变动主要包括：（1）股份期权行使共计发行新股114,000股，募集资金合计HKD 51,578.40；（2）首次公开发售后股份奖励计划本月内再度发行新股141,793股；（3）公司于8月24日、25日及31日分别以每股HKD 1.0042、HKD 1.01及HKD 0.9095回购股份合计200,000股，并将其列为库存股份。此外，公司存在多项股份激励及购股权计划，报告期内部分期权被行使及失效。公司在公告中确认，其就本月股份发行及库存股份变动事宜均符合香港联交所《上市规则》及相关法律法规的要求。本次公告由联席公司秘书李安康博士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.